Silence Therapeutics stock surges as Merck KGaA agrees to acquire the RNA drugmaker for over $1 billion.

By Christy Santhosh Oct 19 (Reuters) - German drugmaker Merck KGaA said on Monday it would acquire UK-based Silence ...

Merck⁠ officially introduced a $500 million, 120,000-square-foot research building featuring automated robotics systems and ...

Arcus Biosciences (RCUS) touted its Merck (MRK)-rivaling kidney cancer treatment results Tuesday, but shares took a swim, ...

Dawn Health, and German science and tech firm Merck KGaA are collaborating to create a model for patient support programs, the latter said Wednesday. Merck KGaA said the companies intend to combine ...

The 130-year-old drugmaker is using Proto’s life-size displays and AI avatars to bring disease-awareness campaigns to ...

Silence Therapeutics PLC (NASDAQ:SLN, FRA:XRP1, OTC:SLNCF), the clinical-stage biotechnology company, surged 59% to $6.11 ...

Silence Therapeutics’ lead siRNA asset for the rare blood cancer polycythemia vera has been earning analyst raves in a tight ...

Germany’s Merck KGaA has agreed to acquire British biotechnology company Silence Therapeutics for approximately $1.3 billion ...

Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA ...

The acquisition will add a Phase III-ready siRNA therapy for polycythaemia vera to Merck’s rare disease pipeline, ...

The Silence Therapeutics acquisition gives Merck KGaA a drug ready for a pivotal test in the blood disorder polycythemia vera ...